Валеология: Здоровье, Болезнь, Выздоровление. 2019; : 24-29
БРОНХОЛЕГОЧНАЯ ДИСПЛАЗИЯ. СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ
Аннотация
Бронхолегочная дисплазия (БЛД) является наиболее распространенным хроническим заболеванием легких у детей грудного возраста. Из-за отсутствия эффективных стратегий профилактики и лечения БЛД в настоящее время представляет собой серьезную проблему, решение которой основывается на необходимости в постоянном поиске новейших данных, а также в проведении современных исследований на фундаментальном, биомедицинском (клеточном) и клиническом уровнях [1]. Правильно поставленные ранние методы диагностики, оказывают огромное влияние на разработки эффективных методов лечения и предотвращения развития тяжелых последствий БЛД. Этот краткий обзор суммирует недавний прогресс в изучении БЛД на современном этапе.
Список литературы
1. Jobe A. H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. (2001);163 : 1723–1729. doi: 10.1164/ajrccm.163.7.2011060
2. Stoecklin B., Simpson S. J., Pillow J. J..Bronchopulmonary dysplasia: Rationale for a pathophysiological rather than treatment based approach to diagnosis. (2018) Dec 19. DOI: 10.1016/j.prrv.2018.12.002
3. Комитет по статистике Министерства национальной экономики РК. Детский фонд ООН. UNICEF. (2017)
4. Savani R. C. Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. (2018) Nov; 42 (7) : 459-470. doi: 10.1053/j.semperi.2018.09.009.
5. Liu L., Oza S., Hogan D., et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. (2016); 388 (10063) : 3027-35.
6. World Health Organization.Born too soon: the global action report on preterm birth. Switzerland (2014); ISBN 978 92 4 450343 0.
7. Blencowe H., Cousens S., Oestergaard M. Z., et all. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. (2012); 379 : 2162–2172.
8. Kair L. R., Leonard D. T., Anderson J. M.. Bronchopulmonary dysplasia. Oregon Health & Science University, Portland, OR, USA.Pediatr Rev. (2012) doi: 10.1542/pir.33-6-255.
9. Abman S. H., Bancalari E., Jobe A. The Evolution of Bronchopulmonary Dysplasia after 50 Years. Am J Respir Crit Care Med. (2017) Feb 15;195 (4) : 421-424. doi: 10.1164/rccm.201611-2386ED.
10. Northway W. H., Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. (1967); 276 : 357–368.
11. Klinger G., Sokolover N., Boyko V., Sirota L., et all., Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweightinfants. Am J Obstet Gynecol. (2013); 208 : 115.e1–9.
12. Abman S. H., Bancalari E., Jobe A. The Evolution of Bronchopulmonary Dysplasia after 50 Years. Am J Respir Crit Care Med. (2017) Feb 15; 195 (4) : 421-424. doi: 10.1164/rccm.201611-2386ED.
13. Baraldi E. I., Filippone M. Chronic lung disease after premature birth. N Engl J Med. (2007) Nov 8; 357 (19) : 1946-55.
14. Northway W. H., Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. (1967); 276:357–368.
15. Abman S. H,, Bancalari E., Jobe A. The evolution of bronchopulmonary dysplasia after 50 years. Am J Respir Crit Care Med. (2017); 195 : 421–424.
16. Day C. L., Ryan R. M. Bronchopulmonary dysplasia: new becomes old again! Pediatr Res. (2017); 81: 210–213.
17. Ryan R. M. A new look at bronchopulmonary dysplasia classification. J Perinatol. (2006); 26 : 207–209.
18. Thomas W., Seidenspinner S., Kramer B. W., et all. Airway angiopoietin-2 in ventilated very preterm infants: association with prenatal factors and neonatal outcome. Pediatr Pulmonol. (2011); 46 : 777–784.
19. Harijith A., Choo-Wing R., et all. A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. (2011); 44 : 621–630.
20. Namasivayam Ambalavanan, M. D., I. Waldemar A. Carlo, et all., for the NICHD/ Cytokines Associated with Bronchopulmonary Dysplasia or Death in Extremely Low Birth Weight Infants/ Pediatrics. (2009) Apr; 123 (4): 1132–1141. doi: 10.1542/peds.2008-0526.
21. Bhandari V., Choo-Wing R., Lee C. G., et all. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. (2006); 12 : 1286–1293.
22. Wang H., St Julien K. R., Stevenson D. K., et all. A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics. (2013); 132 : 290–297.
23. Harijith A., Choo-Wing R.,et all. A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. (2011); 44 : 621–630.
24. Bhandari V., Choo-Wing R., Lee C. G., et all. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. (2006); 12 : 1286–1293.
25. Wang H., St Julien K. R., Stevenson D. K., et all. A genome-wide association study for bronchopulmonary dysplasia. Pediatrics. (2013); 132 : 290–297.
26. Van Marter L. J. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med. (2009);14 : 358–366.
27. Gortner L., Misselwitz B., Milligan D., et all, Members of the MOSAIC Research Group Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. Neonatology. (2011); 99 : 112–117.
28. Mahut B., De Blic J., Emond S., Benoist M. R., et all. Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function. Arch Dis Child Fetal Neonatal Ed. (2007); 92 : F459–F464.
29. Kwinta P., Pietrzyk J. J.. Preterm birth and respiratory disease in later life. Expert Rev Respir Med. (2010); 4 : 593–604.
30. Fakhoury K. F., Sellers C., Smith E. O., Rama J. A., Fan L. L. Serial measurements of lung function in a cohort of young children with bronchopulmonary dysplasia. Pediatrics. (2010); 125: e1441–e1447.
31. Islam J. Y., Keller R. L., Aschner J. L., et all. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med. (2015); 192 : 134–156.
32. Greenough A., Alexander J., Burgess S., et all. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. Arch Dis Child. (2002); 86 : 40–43.
33. Groothuis J. R., Gutierrez K. M., Lauer B. A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. (1988); 82 : 199–203.
34. El Mazloum D., Moschino L., Bozzetto S., Baraldi E. Chronic lung disease of prematurity: long-term respiratory outcome. Neonatology. (2014); 105 : 352–356.
35. Qu Y., Cao Y., Liao M., Lu Z. Sagittal-lung C. T. measurements in the evaluation of asthma-COPD overlap syndrome: a distinctive phenotype from COPD alone. Radiol Med. (2017).
36. Zhu Z., Homer R. J., Wang Z., et all. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production. J. Clin. Invest. (1999); 103 : 779–788.
37. Zhongde Wang,a Tao Zheng, et all. Interferon γ Induction of Pulmonary Emphysema in the Adult Murine Lung. J Exp Med. (2000) Dec 4; 192 (11) : 1587–1600.
38. Bhandari A., Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci (2003); 8 : e370–e380.
39. Bhandari A., Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics (2009); 123 : 1562–1573.
40. Shea L. M., Beehler C., Schwartz M., Shenkar R., Tuder R., Abraham E. Hyperoxia activates NF-kappaB and increases TNF-alpha and IFN-gamma gene expression in mouse pulmonary lymphocytes. J Immunol (2009); 157 : 3902–3908.
41. Kwinta P., Pietrzyk J. J. Preterm birth and respiratory disease in later life. Expert Rev Respir Med. (2010); 4 : 593–608.
42. Lamarche-Vadel A., Blondel B., Truffer P., et all, EPIPAGE Study Group Re-hospitalization in infants younger than 29 weeks’ gestation in the EPIPAGE cohort. Acta Paediatr. (2004); 93 : 1340–1345.
43. Klinger G., Sokolover N., Boyko V., Sirota L., et all. Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweightinfants. Am J Obstet Gynecol. (2013); 240 : 126.
44. Ralser E., Mueller W., Haberland C., et all. Rehospitalization in the first 2 years of life in children born preterm. Acta Paediatr. (2012);101:e1–e5.
45. Bourbon J. R., Boucherat O., Boczkowski J., et all. Bronchopulmonary dysplasia and emphysema: in search of common therapeutic targets. Trends Mol Med (2009); 15 : 169–179.
46. Kaneko, M., Sato, M. Ogasawara, K. Imamura, et all. Serum cytokine concentrations, chorioamnionitis and the onset of bronchopulmonary dysplasia in premature infants / Journal of Neonatal-Perinatal Medicine, (2017) vol. 10, no. 2, pp. 147-155.
47. Savani R. C. Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. (2018); 42 (7) : 459-470. URL: https://pubmed.ncbi.nlm.nih.gov/30446300/.
48. Zubair H. Aghai MD Judy G., et all., IFN‐γ and IP‐10 in tracheal aspirates from premature infants: Relationship with bronchopulmonary dysplasia/Volume48, Issue1,January (2013), Pages 8-13.
49. Köksal N., Kayık B., Çetinkaya M., et all., Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants/ (2012).
50. Stoecklin B., Simpson S. J., Pillow J. J. Bronchopulmonary dysplasia: Rationale for a pathophysiological rather than treatment based approach to diagnosis. Paediatr Respir Rev. (2018) Dec. 19. pii: S1526-0542(18)30166-0.
Valeology: Health - Illnes - recovery. 2019; : 24-29
BRONCHOPULMONARY DYSLASIA. THE CURRENT STATE OF THE PROBLEM
Abstract
Currently, bronchopulmonary dysplasia is the most common complication of prematurity and is a serious problem, the solution of which is based on the need for constant search for the latest data, as well as in modern research. This article reveals the relevance of the study of bronchopulmonary dysplasia at the present stage.
References
1. Jobe A. H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. (2001);163 : 1723–1729. doi: 10.1164/ajrccm.163.7.2011060
2. Stoecklin B., Simpson S. J., Pillow J. J..Bronchopulmonary dysplasia: Rationale for a pathophysiological rather than treatment based approach to diagnosis. (2018) Dec 19. DOI: 10.1016/j.prrv.2018.12.002
3. Komitet po statistike Ministerstva natsional'noi ekonomiki RK. Detskii fond OON. UNICEF. (2017)
4. Savani R. C. Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. (2018) Nov; 42 (7) : 459-470. doi: 10.1053/j.semperi.2018.09.009.
5. Liu L., Oza S., Hogan D., et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. (2016); 388 (10063) : 3027-35.
6. World Health Organization.Born too soon: the global action report on preterm birth. Switzerland (2014); ISBN 978 92 4 450343 0.
7. Blencowe H., Cousens S., Oestergaard M. Z., et all. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. (2012); 379 : 2162–2172.
8. Kair L. R., Leonard D. T., Anderson J. M.. Bronchopulmonary dysplasia. Oregon Health & Science University, Portland, OR, USA.Pediatr Rev. (2012) doi: 10.1542/pir.33-6-255.
9. Abman S. H., Bancalari E., Jobe A. The Evolution of Bronchopulmonary Dysplasia after 50 Years. Am J Respir Crit Care Med. (2017) Feb 15;195 (4) : 421-424. doi: 10.1164/rccm.201611-2386ED.
10. Northway W. H., Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. (1967); 276 : 357–368.
11. Klinger G., Sokolover N., Boyko V., Sirota L., et all., Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweightinfants. Am J Obstet Gynecol. (2013); 208 : 115.e1–9.
12. Abman S. H., Bancalari E., Jobe A. The Evolution of Bronchopulmonary Dysplasia after 50 Years. Am J Respir Crit Care Med. (2017) Feb 15; 195 (4) : 421-424. doi: 10.1164/rccm.201611-2386ED.
13. Baraldi E. I., Filippone M. Chronic lung disease after premature birth. N Engl J Med. (2007) Nov 8; 357 (19) : 1946-55.
14. Northway W. H., Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. (1967); 276:357–368.
15. Abman S. H,, Bancalari E., Jobe A. The evolution of bronchopulmonary dysplasia after 50 years. Am J Respir Crit Care Med. (2017); 195 : 421–424.
16. Day C. L., Ryan R. M. Bronchopulmonary dysplasia: new becomes old again! Pediatr Res. (2017); 81: 210–213.
17. Ryan R. M. A new look at bronchopulmonary dysplasia classification. J Perinatol. (2006); 26 : 207–209.
18. Thomas W., Seidenspinner S., Kramer B. W., et all. Airway angiopoietin-2 in ventilated very preterm infants: association with prenatal factors and neonatal outcome. Pediatr Pulmonol. (2011); 46 : 777–784.
19. Harijith A., Choo-Wing R., et all. A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. (2011); 44 : 621–630.
20. Namasivayam Ambalavanan, M. D., I. Waldemar A. Carlo, et all., for the NICHD/ Cytokines Associated with Bronchopulmonary Dysplasia or Death in Extremely Low Birth Weight Infants/ Pediatrics. (2009) Apr; 123 (4): 1132–1141. doi: 10.1542/peds.2008-0526.
21. Bhandari V., Choo-Wing R., Lee C. G., et all. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. (2006); 12 : 1286–1293.
22. Wang H., St Julien K. R., Stevenson D. K., et all. A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics. (2013); 132 : 290–297.
23. Harijith A., Choo-Wing R.,et all. A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. (2011); 44 : 621–630.
24. Bhandari V., Choo-Wing R., Lee C. G., et all. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. (2006); 12 : 1286–1293.
25. Wang H., St Julien K. R., Stevenson D. K., et all. A genome-wide association study for bronchopulmonary dysplasia. Pediatrics. (2013); 132 : 290–297.
26. Van Marter L. J. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med. (2009);14 : 358–366.
27. Gortner L., Misselwitz B., Milligan D., et all, Members of the MOSAIC Research Group Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. Neonatology. (2011); 99 : 112–117.
28. Mahut B., De Blic J., Emond S., Benoist M. R., et all. Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function. Arch Dis Child Fetal Neonatal Ed. (2007); 92 : F459–F464.
29. Kwinta P., Pietrzyk J. J.. Preterm birth and respiratory disease in later life. Expert Rev Respir Med. (2010); 4 : 593–604.
30. Fakhoury K. F., Sellers C., Smith E. O., Rama J. A., Fan L. L. Serial measurements of lung function in a cohort of young children with bronchopulmonary dysplasia. Pediatrics. (2010); 125: e1441–e1447.
31. Islam J. Y., Keller R. L., Aschner J. L., et all. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med. (2015); 192 : 134–156.
32. Greenough A., Alexander J., Burgess S., et all. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. Arch Dis Child. (2002); 86 : 40–43.
33. Groothuis J. R., Gutierrez K. M., Lauer B. A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. (1988); 82 : 199–203.
34. El Mazloum D., Moschino L., Bozzetto S., Baraldi E. Chronic lung disease of prematurity: long-term respiratory outcome. Neonatology. (2014); 105 : 352–356.
35. Qu Y., Cao Y., Liao M., Lu Z. Sagittal-lung C. T. measurements in the evaluation of asthma-COPD overlap syndrome: a distinctive phenotype from COPD alone. Radiol Med. (2017).
36. Zhu Z., Homer R. J., Wang Z., et all. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production. J. Clin. Invest. (1999); 103 : 779–788.
37. Zhongde Wang,a Tao Zheng, et all. Interferon γ Induction of Pulmonary Emphysema in the Adult Murine Lung. J Exp Med. (2000) Dec 4; 192 (11) : 1587–1600.
38. Bhandari A., Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci (2003); 8 : e370–e380.
39. Bhandari A., Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics (2009); 123 : 1562–1573.
40. Shea L. M., Beehler C., Schwartz M., Shenkar R., Tuder R., Abraham E. Hyperoxia activates NF-kappaB and increases TNF-alpha and IFN-gamma gene expression in mouse pulmonary lymphocytes. J Immunol (2009); 157 : 3902–3908.
41. Kwinta P., Pietrzyk J. J. Preterm birth and respiratory disease in later life. Expert Rev Respir Med. (2010); 4 : 593–608.
42. Lamarche-Vadel A., Blondel B., Truffer P., et all, EPIPAGE Study Group Re-hospitalization in infants younger than 29 weeks’ gestation in the EPIPAGE cohort. Acta Paediatr. (2004); 93 : 1340–1345.
43. Klinger G., Sokolover N., Boyko V., Sirota L., et all. Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweightinfants. Am J Obstet Gynecol. (2013); 240 : 126.
44. Ralser E., Mueller W., Haberland C., et all. Rehospitalization in the first 2 years of life in children born preterm. Acta Paediatr. (2012);101:e1–e5.
45. Bourbon J. R., Boucherat O., Boczkowski J., et all. Bronchopulmonary dysplasia and emphysema: in search of common therapeutic targets. Trends Mol Med (2009); 15 : 169–179.
46. Kaneko, M., Sato, M. Ogasawara, K. Imamura, et all. Serum cytokine concentrations, chorioamnionitis and the onset of bronchopulmonary dysplasia in premature infants / Journal of Neonatal-Perinatal Medicine, (2017) vol. 10, no. 2, pp. 147-155.
47. Savani R. C. Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. (2018); 42 (7) : 459-470. URL: https://pubmed.ncbi.nlm.nih.gov/30446300/.
48. Zubair H. Aghai MD Judy G., et all., IFN‐γ and IP‐10 in tracheal aspirates from premature infants: Relationship with bronchopulmonary dysplasia/Volume48, Issue1,January (2013), Pages 8-13.
49. Köksal N., Kayık B., Çetinkaya M., et all., Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants/ (2012).
50. Stoecklin B., Simpson S. J., Pillow J. J. Bronchopulmonary dysplasia: Rationale for a pathophysiological rather than treatment based approach to diagnosis. Paediatr Respir Rev. (2018) Dec. 19. pii: S1526-0542(18)30166-0.
